Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

NCT00416208 ·Status: COMPLETED ·Phase: PHASE3

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

NCT06846905 ·Status: RECRUITING

Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

NCT01021592 ·Status: COMPLETED

Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

NCT00570180 ·Status: COMPLETED ·Phase: PHASE2

Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment

NCT04309942 ·Status: COMPLETED ·Phase: NA

A Retreatment Study With Bortezomib for Multiple Myeloma

NCT01030302 ·Status: COMPLETED

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

NCT04751877 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

NCT02197221 ·Status: COMPLETED ·Phase: PHASE3

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT06485076 ·Status: RECRUITING ·Phase: NA

Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

NCT00367185 ·Status: COMPLETED ·Phase: PHASE3

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

NCT00416273 ·Status: COMPLETED ·Phase: PHASE3

An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice

NCT02902900 ·Status: COMPLETED

Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

NCT02086942 ·Status: UNKNOWN ·Phase: PHASE2

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

NCT00652041 ·Status: COMPLETED ·Phase: PHASE4

Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting

NCT05041933 ·Status: UNKNOWN

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

NCT01453088 ·Status: TERMINATED ·Phase: PHASE2

Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

NCT00291538 ·Status: COMPLETED ·Phase: PHASE1

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

NCT03051841 ·Status: UNKNOWN ·Phase: PHASE1

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

NCT04268199 ·Status: RECRUITING ·Phase: PHASE2

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

NCT01208766 ·Status: COMPLETED ·Phase: PHASE3

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies

NCT02997813 ·Status: COMPLETED

Multiple Myeloma Minimal Residual Disease

NCT02627261 ·Status: COMPLETED

Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma

NCT05355987 ·Status: COMPLETED ·Phase: NA

Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.

NCT02063113 ·Status: TERMINATED ·Phase: NA

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

NCT02474563 ·Status: COMPLETED